LakeShore Biopharma (LSBCF)
OTHER OTC:LSBCF
LSBCF Stock Chart & Stats
$0.85
--
Market closed
$0.85
--
Day’s Range― - ―
52-Week Range$0.03 - $1.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.12K
Market Cap
$1.28M
Enterprise Value$395.04M
Total Cash (Recent Filing)$246.35M
Total Debt (Recent Filing)$424.46M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Apr 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,212,692
10 Day Avg. Volume4,144
30 Day Avg. Volume5,120
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)3.80
Price to Sales (P/S)3.09
P/FCF Ratio-13.69
Enterprise Value/Market Cap309.21
Enterprise Value/Revenue0.68
Enterprise Value/Gross Profit1.02
Enterprise Value/Ebitda-1.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.7
Revenue Forecast (FY)$1.80B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained gross margins above 75% point to durable product-level profitability and pricing power. High gross margins provide structural support for covering fixed costs, funding R&D or commercialization, and improving operating leverage as revenue scales over the next several quarters.
Improving Leverage TrendsAn improving debt-to-equity trend signals management progress in managing liabilities and refinancing risk. Better leverage enhances financial flexibility to withstand operating shortfalls and pursue restructuring or strategic transactions over the medium term.
Active Strategic / Take‑private InterestConcrete buyer interest and a revised acquisition proposal create a viable strategic exit or recapitalization path. A successful transaction could resolve balance-sheet stress, provide immediate liquidity to stakeholders, and enable business reorganization away from public market constraints.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows materially weaken liquidity and constrain the company's ability to self-fund operations, R&D, or commercial expansion. This increases dependence on external financing or asset dispositions and elevates medium‑term solvency risk.
Ongoing Net Losses And Weak ProfitabilityNegative EBIT and net margins show the company cannot yet cover operating expenses despite high gross margins. Sustained losses erode equity, depress ROE, and limit reinvestment capacity, making durable profitability contingent on meaningful cost reductions or revenue scale-up.
Material Arbitration Awards And Governance RiskLarge arbitration liabilities and an active fraud probe create significant balance-sheet, legal, and governance uncertainty. Potential cash outflows, contested tribunals, and leadership culpability can impair operations, deter financing, and may void or delay strategic deals, posing lasting downside risk.
LakeShore Biopharma News
LSBCF FAQ
What was LakeShore Biopharma’s price range in the past 12 months?
LakeShore Biopharma lowest stock price was $0.03 and its highest was $1.79 in the past 12 months.
What is LakeShore Biopharma’s market cap?
LakeShore Biopharma’s market cap is $1.28M.
When is LakeShore Biopharma’s upcoming earnings report date?
LakeShore Biopharma’s upcoming earnings report date is Apr 17, 2026 which is in 4 days.
How were LakeShore Biopharma’s earnings last quarter?
Currently, no data Available
Is LakeShore Biopharma overvalued?
According to Wall Street analysts LakeShore Biopharma’s price is currently Overvalued.
Does LakeShore Biopharma pay dividends?
LakeShore Biopharma does not currently pay dividends.
What is LakeShore Biopharma’s EPS estimate?
LakeShore Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LakeShore Biopharma have?
LakeShore Biopharma has 41,212,692 shares outstanding.
What happened to LakeShore Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of LakeShore Biopharma?
Currently, no hedge funds are holding shares in LSBCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LakeShore Biopharma
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
Technical Analysis
Ownership Overview
―
Insiders
0.39% Other Institutional Investors
99.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---